CS
ALBO

Credit Suisse’s Albireo Pharma Inc ALBO Stock Holding History

Credit Suisse’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,280
Closed -$244K – 3928
2022
Q4 		$244K Sell
11,280
-136
-1% -$2.87K ﹤0.01% 3116
2022
Q3 		$221K Buy
11,416
+81
+0.7% +$1.68K ﹤0.01% 3210
2022
Q2 		$225K Buy
11,335
+489
+5% +$12.9K ﹤0.01% 3290
2022
Q1 		$324K Buy
10,846
+734
+7% +$21.5K ﹤0.01% 3188
2021
Q4 		$235K Buy
10,112
+833
+9% +$22.1K ﹤0.01% 4218
2021
Q3 		$290K Buy
9,279
+79
+0.9% +$2.44K ﹤0.01% 4099
2021
Q2 		$324K Sell
9,200
-2,828
-24% -$91.9K ﹤0.01% 4083
2021
Q1 		$424K Sell
12,028
-6,901
-36% -$255K ﹤0.01% 3867
2020
Q4 		$711K Buy
+18,929
New +$688K ﹤0.01% 3591
2018
Q2 		– Sell
-6,939
Closed -$226K – 4197
2018
Q1 		$226K Buy
+6,939
New +$234K ﹤0.01% 3675
2013
Q4 		– Sell
-1,529
Closed -$144K – 4740
2013
Q3 		$144K Buy
+1,529
New +$199K ﹤0.01% 4054

Other funds holding ALBO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Credit Suisse's ALBO Position: Q1 2023 in Review

Credit Suisse sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 11,280 shares — an estimated $244K sold.

Credit Suisse first reported a position in ALBO in Q3 2013 and held it in 11 quarters. The position peaked at $711K in Q4 2020. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Credit Suisse reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 11,280 Albireo Pharma Inc shares in Q1 2023, an estimated $244K.
  • Credit Suisse first reported a position in Albireo Pharma Inc in Q3 2013 and held it in 11 quarters.
  • Credit Suisse's Albireo Pharma Inc position peaked at $711K in Q4 2020.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.